Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153077 | 0.94 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL29737207 | 0.94 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL560927 | 0.94 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL153900 | 0.94 | ADRB2 (0.98) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL561414 | 0.94 | ADRB2 (0.98) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL4709183 | 0.92 | ADRB2 (0.95) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL561509 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL153578 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL561092 | 0.90 | ADRB2 (0.98) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL153670 | 0.90 | ADRB2 (0.98) | ADRB2ADRB1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-2313397-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010015522-A1 | CYCLOHEXYLOXY-SUBSTITUTED HETEROCYCLICS, MEDICINES CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | ADRB2 55/4885ADRB1 58/4885CHRM2 75/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ADRB2 1410/4885ADRB1 887/4885CHRM2 220/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | ADRB2 50/4885ADRB1 80/4885CHRM2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.